Haisco Pharma's innovative drug HSK47388 receives IND application approval

Haisco Pharmaceutical Group (SZSE:002653) has received notification from the National Medical Products Administration (NMPA) that its Investigational New Drug (IND) application for HSK47388 tablets has been accepted. HSK47388, an internally developed oral drug, is designed as a highly selective treatment for autoimmune diseases, classified as a Category 1 chemical drug. Preclinical studies suggest that HSK47388 effectively suppresses inflammatory responses in rats and exhibits a favorable safety profile. While the company pursues development of this promising drug, Director and CEO Fan Xiulian stepped down from her position due to retirement, with rigorous procedure for candidate replacement followed.